Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | CD81 | P60033 | 2/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9133444 | 1.00 | EP300 (0.39) | EP300CD81TBXAS1PPARGTRPA1 | |
| SCHEMBL3680117 | 0.93 | EP300 (0.42) | EP300CD81TBXAS1PPARGTRPA1 | |
| SCHEMBL982294 | 0.93 | EP300 (0.42) | EP300CD81TBXAS1PPARGTRPA1 | |
| SCHEMBL8624377 | 0.91 | EP300 (0.45) | EP300CD81TBXAS1PPARGBACE1 | |
| SCHEMBL8620371 | 0.91 | EP300 (0.45) | EP300CD81TBXAS1PPARGBACE1 | |
| SCHEMBL9130972 | 0.91 | EP300 (0.45) | EP300CD81TBXAS1PPARGBACE1 | |
| SCHEMBL8624369 | 0.91 | EP300 (0.45) | EP300CD81TBXAS1PPARGBACE1 | |
| SCHEMBL9133542 | 0.91 | EP300 (0.45) | EP300CD81TBXAS1PPARGBACE1 | |
| SCHEMBL9130970 | 0.91 | EP300 (0.45) | EP300CD81TBXAS1PPARGBACE1 | |
| SCHEMBL8620367 | 0.91 | EP300 (0.45) | EP300CD81TBXAS1PPARGBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188627-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2017-10-26 | — | — | US | disclosed |
| WO-2016057660-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-9103965-B2 | Amphiphilic siloxane-containing vinylic monomers and uses thereof | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140171542-A1 | AMPHIPHILIC SILOXANE-CONTAINING VINYLIC MONOMERS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-7960026-B2 | Organic-inorganic composite particle and process for preparation thereof | ROHM AND HAAS COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090017304-A1 | Organic-inorganic composite particle and process for preparation thereof | KOLLER ANNE DENISE | 2009-01-15 | — | — | US | disclosed |
| US-7265166-B2 | Aqueous polymer composition | ROHM AND HAAS COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060189748-A1 | AQUEOUS POLYMERIC COMPOSITION CONTAINING POLYMERIC NANOPARTICLES AND TREATMENTS PREPARED THEREFROM | ROHM AND HAAS COMPANY | 2006-08-24 | — | — | US | disclosed |
| US-7091275-B1 | Aqueous polymeric composition containing polymeric nanoparticles and treatments prepared therefrom | ROHM AND HAAS COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| US-5441731-A | A ion exchange resin based on a cationic polymer of an alkyl alkacrylate, a oligoyalkylene glycol dimethacrylate acid and a trialkylammonioalkyl methacrylate; antichloesterol agent | SMITHKLINE & FRENCH LABORATORIES LTD. (GB) | 1995-08-15 | — | — | US | disclosed |
| EP-0373852-B1 | Compounds | SMITH KLINE FRENCH LAB (GB) | 1994-10-26 | — | — | EP | disclosed |
| EP-0373852-A2 | Compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188627-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | EP300 488/4885CD81 4680/4885TBXAS1 475/4885 |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | EP300 488/4885CD81 4680/4885TBXAS1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.